INTRODUCTION
============

G protein-coupled receptors (GPCRs) comprise the largest subset of cell surface receptors which transduce signals via coupling to heterotrimeric G proteins and are extensively involved in the fine-tuning of physiological processes. They constitute at least 3% of the human genome and have great pathophysiological importance with an abundance of information indicating their dysfunction to be associated with diseases such as diabetes, visual disability, and chronic inflammation. As a result, at least 30--40% of pharmaceutical drugs developed are targeted at GPCRs. Traditionally, GPCRs were recognized to elicit physiological responses via coupling as monomeric units to G proteins in a 1:1 stoichiometric ratio. However there is now a growing body of evidence confirming that GPCRs can self-associate or associate with different receptors to form homo-and/or hetero-oligomers. With the wealth of information recently discovered, oligomerization has been implicated to play important roles in maturation, cell surface delivery, signaling, and internalization of GPCRs. The concept of oligomerization is groundbreaking as it not only widens our perspective in understanding the molecular determinants to receptor regulation and function, but also provides new opportunities in the development of personalized drug treatments. In recent years, the small 15-member class B \[secretin (SCT) or class II\] GPCRs are emerging as oligomerization candidates with efforts contributed predominantly by Laurence Miller's and Dominik Schelshorn's groups. In this article, we will provide an overview of the history of oligomerization and review the available information on class B GPCRs and its functional implications.

EARLY EVIDENCE OF GPCR DIMERIZATION BY PHARMACOLOGICAL AND BIOCHEMICAL APPROACHES
=================================================================================

Although GPCR oligomerization is now a widely accepted phenomenon with modern non-radiative techniques such as resonance energy transfer (RET) strategies that are effective in demonstrating homo- and/or hetero-oligomer interactions, early clues to their existence were often indirect and overlooked. In 1975, a binding experiment of a potent antagonist to β~2~-adrenergic receptors (ADRB2) in frog erythrocyte membranes led to findings of negative cooperativity among binding sites ([@B53]; [@B52]). This was pioneering evidence for oligomerization and can be better explained as site--site interactions amongst ADRB2 oligomers based on today's knowledge. Soon after, radiation inactivation, cross-linking and co-immunoprecipitation studies have also provided biochemical evidence complementing earlier observations of oligomerization. For example, immunoaffinity chromatography and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) showed the subunit molecular weight of mammalian lung ADRB2 to be 59 kDa, while radiation inactivation of ADRB2 resulted in a functional subunit molecular weight of 109 kDa ([@B22]). Taken together, the contrasting molecular sizes indicate that ADRB2s exist in the membrane as dimers of two subunits ([@B22]). Similar suggestions have also been made for the rat liver membrane α~1~-adrenergic receptor (ADRA1; [@B98]) and human platelet α~2~-adrenergic receptor (ADRA2; [@B99]) which each have molecular masses of 160 kDa. Alternatively, cross-linking experiments, using photoaffinity labeling reagents, cell permeable cross-linkers, agonists, and antagonists ([@B8]; [@B69]; [@B28]; [@B82]; [@B10]; [@B84]; [@B92]) have been used to study the dimeric nature of angiotensin II (ANGII) receptors. Using similar methods, other GPCRs such as the dopamine D~2~ ([@B66]), calcium-sensing ([@B4]), and chemokine ([@B80]) receptors have also been demonstrated to exist as dimeric units. Other experiments such as photoaffinity labeling of MRs from various brain regions and the heart have also provided evidence for the presence of inter convertible dimers and tetramers ([@B2]). The idea of higher order oligomerization was further supported by comparable findings of thyrotropin hormone receptor complexes ([@B25]).

In the 1990s, another line of evidence demonstrating GPCR oligomerization stemmed from *trans*-complementation, and dominant-negative and -positive effect studies on co-expression of chimeric and mutant receptor constructs. One of the first experiments of these series was performed in 1993 by co-expression of chimeric muscarinic and adrenergic receptors composed of their C-terminal units ([@B55]). Although no binding activity was detected when the chimeras were expressed individually, co-expression restored ligand binding to a level comparable to wild-type receptors and allowed agonist-dependent phospholipase C (PLC) activation ([@B55]). These observations were explained as molecular interaction of the chimeras restoring functionality in a heteromeric complex ([@B55]). Other *trans*-complementation studies for GPCRs such as the ANGII type 1a (AGTR1a; [@B65]), somatostatin (SST -- SST~1~ and SST~5~; [@B79]) and dopamine (D~2~ and D~3~; [@B89]) receptors have also provided useful information in support of GPCR oligomerization. This concept was further explored in experiments showing dominant-negative or -positive effects such those observed with the antidiuretic V2 vasopressin ([@B108]) and ADRB2 ([@B38]), respectively. Although there are reports of different functional effects, the various studies described are useful in offering more clues to molecular interactions amongst GPCRs.

Though earlier experiments provided a large pool of information suggesting GPCR oligomerization, there was still no direct evidence to support this concept. Early western blot studies often showed presence of immuno-reactive bands with molecular masses two or more times greater than a single receptor ([@B37]). Western blot was later performed in combination with immunoprecipitation using antibodies to endogenous or epitope tagged-receptors, providing for the first time direct evidence of GPCR interaction. Using this technique, homodimerization of ADRB2 ([@B39]) was demonstrated. For example, cross-species oligomerization was also detected in select serotonin receptors with lysophosphatidic acid receptors 1 and 3 and γ-aminobutyric acid B~2~ receptors ([@B87]), dopamine D~1~ and D~2~ receptors ([@B51]), and α~1b~ and β~2~ adrenergic receptors ([@B95]).

RET APPROACH IN GPCR OLIGOMERIZATION
====================================

Since the days of radioactive inactivation experiments, the concept of GPCR oligomerization has been confirmed with emergence of biophysical data providing more in-depth evidence. In the last decade, RET techniques have gained popularity and are one of the best resolution strategies developed for direct study of GPCR interactions. The basis of these techniques lies in non-radiative energy transfer from an excited "donor" molecule to an "acceptor" ([@B104]). Bioluminescence RET (BRET) and fluorescence RET (FRET) are two of the most widely used RET approaches. BRET relies on a naturally occurring biophysical process in marine species between a luminescent donor and fluorescent acceptor, while only fluorescent molecules are utilized in FRET ([@B104]). These have provided advantages over traditional biochemical methods including high signal to noise ratios, use of intact cells, precise targeting of fusion receptors and actual quantification of the proportion and type of GPCR oligomers formed, and therefore are currently the most commonly used methods. Based on these approaches, a wide range of GPCRs have since been identified to function as oligomers, including the yeast α-factor ([@B67]), dopamine D~2~ ([@B105]), thyrotropin ([@B49], [@B50]), opioid ([@B78]), neuropeptide Y ([@B16]), melatonin ([@B3]), adrenergic ([@B62]; [@B78]; [@B9]), and chemokine ([@B73]) receptors. Despite the successes in identifying various oligomers, there are several drawbacks of the BRET and FRET techniques. With regards to these aforementioned RET techniques, a primary concern is that the signals generated cannot be used to discriminate between non-mature and mature proteins within the various cellular locations (e.g., intracellular complexes and plasma membrane; [@B23]; [@B12]). Therefore, the information provided is essentially limited and more steps may be needed to address this concern. Moreover, another drawback of BRET and FRET is potential bleed-through artifacts which may be due to spectral overlaps, substrate instability, and auto-luminescence from serum containing medium, which together skew the interpretation of the results ([@B74]; [@B23]). Therefore, the careful use of appropriate controls and fluorescent molecules need to be considered when using these RET techniques for the study of oligomerization. More recently, homogeneous time-resolved fluorescence (HTRF) which combines FRET with time-resolved measurements has also been considered. HTRF provides the advantage of increasing assay sensitivity and accuracy via replacing donor molecules with rare-earth lanthanides (e.g., europium cryptate) whose properties include non-auto-fluorescence and long emission half-lives ([@B13]). Using HTRF, a number of receptors have been identified to dimerize, e.g., GABA ([@B59]) and metabotropic glutamate-like receptors ([@B83]; [@B6]) and oligomerize, e.g., dopamine D~2~ ([@B29]) and histamine H4 ([@B1]) receptors. Fluorescence life-time imaging microscopy (FLIM) is also useful in overcoming the drawback of the use of intact cells and bleed-through in BRET and FRET assays. Moreover, FLIM can also provide useful information on the proportion of non-dimerizing and dimerizing partners and also visual images indicating where the signals are localized, for example the dimerization of the transcription factor CCAAT and enhancer binding protein-α in live mouse pituitary cell nuclei ([@B93]).

OLIGOMERIZATION OF CLASS B GPCRs
================================

Although techniques in studying oligomerization have existed for more than three decades, information with regards to the class B GPCRs is still in its infancy and largely contributed by the newer RET techniques. In class A GPCRs, several important interfaces including the transmembrane (TM) domains have been identified to contribute toward oligomerization. Moreover, oligomerization has also been shown to play a role in modulating function, via altering parameters such as ligand binding, signaling, and trafficking. Though the SCT receptor (SCTR) remains to be the most extensively studied class B GPCR, information regarding other class B GPCRs continues to grow. Collectively, the SCT superfamily of hormones and receptors represent important drug targets due to their physiological roles in glucose homeostasis, feeding behavior, and vascular contractility. They are characterized by a large N-terminal extracellular domain (ECD) containing six cysteine residues for disulfide bond formation and *N*-glycosylation sites for receptor conformation and ligand binding. The N-terminal ectodomain is linked to seven hydrophobic TM domains arranged in α-helical bundles connected by three exoloops, three endoloops, and a short cytosolic C-terminus ([@B64]). Currently, there are intense efforts to link the various structural domains to oligomerization in hopes of unraveling the specific molecular determinants that may affect certain pathological conditions. Taken together, information regarding the oligomerization of class B GPCRs will be highly valuable in enhancing the specificity of future drug design.

SECRETIN RECEPTORS
------------------

The SCTR was first cloned from the rat in 1991 ([@B43]) and is now recognized as one of the most extensively studied class B GPCRs, and the first that was demonstrated to have the ability to form oligomers. By investigating wild-type and exon-3 splice variants using confocal imaging and BRET, SCTR has been shown to be capable of homo- and heterodimerization ([@B14],[@B15]; **Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}**). When expressed alone, the exon-3 splice variant receptors lack SCT binding and signaling activity but are able to traffic normally to the cell surface. However, co-expression of the variant with the wild-type SCT results in a dominant-negative effect, indicating direct physical interaction. Since the variant receptor is predominantly expressed, comprising up to 70% of SCTRs in gastrinoma, over the wild-type receptor, heterodimerization has been suggested to be an underlying factor in facilitating tumor growth through its dominant-negative effects. This study in 2002 was a breakthrough for class B GPCRs, showing the first physiological relevance of class B GPCR oligomerization. Taken together with data from subsequent studies, SCTR homodimerization is now recognized to occur, independent of ligand binding ([@B14]; [@B34]).

###### 

Homodimerization of class B GPCRs.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Homodimer             Technique                 Key domain                                                                      Reference
  --------------------- ------------------------- ------------------------------------------------------------------------------- ----------------------------------------
  SCTR/SCTR             Morphological FRET\       GxxxG motif independent\                                                        [@B14], [@B34], [@B35], [@B32], [@B54]
                        BRET                      Lipid-exposed TM4 residues (human: Gly^243^, Ile^247^)                          

  GCGR/GCGR             BRET                      n/a                                                                             [@B81], [@B90]

  GLP1R/GLP1R           BRET                      n/a                                                                             [@B90], [@B100]

  GLP2R/GLP2R           BRET                      n/a                                                                             [@B90]

  GIPR/GIPR             BRET                      n/a                                                                             [@B90], [@B100]

  VIPR1/ VIPR1          Immunohistochemistry\     n/a                                                                             [@B34]
                        Co-immunoprecipitation\                                                                                   
                        Morphological FRET\                                                                                       
                        BRET                                                                                                      

  VIPR2/VIPR2           Morphological FRET\       n/a                                                                             [@B34]
                        BRET                                                                                                      

  ADCYAP1R1/ADCYAP1R1   Time-resolved FRET        n/a                                                                             [@B58]

  GHRHR/GHRHR           Co-immunoprecipitation                                                                                    [@B61]

  PTHR1/PTHR1           Crystallography\          ECD α-helix (human: Ile^135^, Arg^179^, Val^183^, Leu^187^)                     [@B75]
                        FRET\                                                                                                     
                        BRET                                                                                                      

  CALCR/CALCR           Co-immunoprecipitation\   Lipid-exposed TM4 residues (human: Arg^236^, Val^250^, Thr^253^)\               [@B91], [@B31]
                        FRET\                     C-terminal tail                                                                 
                        BRET                                                                                                      

  CALCRL/CALCRL         Co-immunoprecipitation\   n/a                                                                             [@B41]
                        FRET\                                                                                                     
                        BRET                                                                                                      

  CRHR1/CRHR1           FRET\                     Pseudo signal peptide (based on rat CRHR2a: Asn^13^ prevents oligomerization)   [@B46], [@B107], [@B94]
                        BRET                                                                                                      
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Techniques used for study and domains indicated to be important are described. SCTR, secretin receptor; GCGR, glucagon receptor; GLP1R, glucagon-like peptide 1 receptor; GLP2R, glucagon-like peptide 2 receptor; GIPR, glucose-dependent insulinotropic polypeptide receptor; VIPR1, vasoactive intestinal peptide (VIP) receptor 1; VIPR2, VIP receptor 2; ADCYAP1R1, PACAP type 1 receptor; GHRHR, growth hormone-releasing hormone receptor; PTHR1, parathyroid hormone receptor type 1; CALCR, calcitonin receptor; CALCRL, CALCR-like receptor; CRHR, corticotropin-releasing hormone receptor; FRET, fluorescence resonance energy transfer; BRET, bioluminescence resonance energy transfer; n/a, information not available.

###### 

Heterodimerization of class B GPCRs.

  --------------------------------------------------------------------------
  Heterodimer   Technique                     Key domain   Reference
  ------------- ----------------------------- ------------ -----------------
  SCTR/GLP1R    BRET                          n/a          [@B33]

  SCTR/GLP2R    BRET                          n/a          [@B33]

  SCTR/VIPR1    Morphological FRET\           n/a          [@B34], [@B33]
                BRET                                       

  SCTR/VIPR2    Morphological FRET\           n/a          [@B34], [@B33]
                BRET                                       

  SCTR/GHRHR    BRET                          n/a          [@B33]

  SCTR/PTHR1    BRET                          n/a          [@B33]

  SCTR/PTHR2    BRET                          n/a          [@B33]

  SCTR/CALCRL   BRET                          n/a          [@B33]

  GCGR/GLP1R    BRET                          n/a          [@B81], [@B90]

  GCGR/GLP2R    BRET                          n/a          [@B90]

  GCGR/GIPR     BRET                          n/a          [@B90]

  GLP1R/GIPR    BRET                          n/a          [@B90], [@B100]

  GLP2R/GIPR    BRET                          n/a          [@B90]

  VIPR1/VIPR2   Co-immunoprecipitation BRET   n/a          [@B34]
  --------------------------------------------------------------------------

To decipher the molecular determinants of oligomerization, receptors with mutated N- and C- terminal domains were studied ([@B54]). Mutant receptors, as expected, were unable to bind SCT or sort efficiently to the plasma membrane, but the ability to still produce BRET signals above background suggested that the TM spanning core alone was sufficient for oligomerization ([@B54]). Moreover, SCTR dimerization was also found to be independent of the GxxxG helix--helix motif ([@B54]), which is essential for oligomerization of class A receptors, such as the yeast α-factor ([@B68]) and β~2~ adrenergic ([@B86]) receptors. In addition, FRET signals within organelles of the receptor biosynthetic pathway including the endoplasmic reticulum, Golgi clusters, and plasma membrane were also detected, suggesting the occurrence of oligomerization even during the maturation of nascent molecules ([@B54]). To further explore the domains responsible for homodimerization, TM peptide competition experiments have been performed. Of the seven TM peptides applied, TM4 was the only segment that disrupted BRET signals, suggesting it to be a functionally important interface for oligomerization ([@B35]). Using alanine mutagenesis, the contribution of TM4 in SCTR oligomers was pinpointed to two lipid-facing residues: Gly^243^ and Ile^247^ ([@B35]). Although no direct pathophysiological connection has been made regarding these new data, reduced signaling of monomeric forms suggests that SCTR dimers are necessary in optimizing functionality ([@B35]). Most recently, bimolecular luminescence complementation and BRET experiments have clarified SCTR's existence as homodimers and not higher order oligomers ([@B32]). Therefore, previous references to oligomerization of SCTRs should be referred to as homodimerization unless otherwise stated. Aside from homodimers, SCTRs have also been implicated to form heterodimers with a wide range of class B GPCRs, including the glucagon-like peptide 1 receptor (GLP1R), glucagon-like peptide 2 receptor (GLP2R), vasoactive intestinal peptide receptor 1 (VIPR1), vasoactive intestinal peptide receptor 2 (VIPR2), growth hormone-releasing hormone receptor (GHRHR), parathyroid hormone 1 receptor (PTHR1), parathyroid hormone 2 receptor (PTHR2), and calcitonin receptor-like (CALCRL; [@B34], [@B33]; **Table [2](#T2){ref-type="table"}**).

GCG, GLP1, GLP2, AND GIP RECEPTORS
----------------------------------

Receptors for glucagon (GCG), glucagon-like peptide 1 (GLP1), glucagon-like peptide 2 (GLP2), and glucose-independent insulinotropic polypeptide (GIP) are well-known regulators of carbohydrate, fat, and protein metabolism. Oligomerization within the GCG subfamily of receptors was recently identified but with some controversy ([@B81]; [@B90]). Homodimerization of each GCG family receptor member has been reported through BRET experiments ([@B90]), however, these events remained unconfirmed with the lack of appropriate negative controls and the fact that another group was unable to repeat some of these results ([@B81]). Amongst the receptors, the GCG receptor (GCGR) and GIP receptor (GIPR) exhibited the strongest ability to homodimerize but BRET signals were slightly reduced upon application of GCG or GIP, while the GLP receptors were weakly responsive and unaffected by agonist stimulation ([@B90]). Further studies with BRET saturation experiments confirmed GLP1R and GIPR homodimerization, with some agonist-induced reduction ([@B90]). On the basis of these results, it was suggested that ligand binding leads to a decrease in affinity and conformational change of the homodimers ([@B90]). In a similar study, the same BRET saturation results were obtained for the GLP1R, however no changes were observed when GLP1 was added ([@B81]). This was similarly the case for GCGRs ([@B81]). Taken together, it is highly likely that the GCG subfamily receptors are able to form homodimers (**Table [1](#T1){ref-type="table"}**), while further studies with appropriate use of controls are necessary to solidify this conclusion.

Despite the controversy, heterodimerization of GLP1R and GIPR has been confirmed by BRET saturation and kinetic experiments ([@B81]; [@B90]; [@B100]; **Table [2](#T2){ref-type="table"}**). The heterodimerization event between GLP1R and GIPR was found to be dose-dependently induced by GLP1 and inhibited by GIP ([@B90]). Further application of GLP1 and its antagonists to this system showed heterodimerization to occur independently to GLP1R activation, but was induced by ligand binding, with BRET signals reaching a maximum 10--30 s after addition of GLP1 ([@B90]). More specifically, the heterodimers were suggested to play a role in allosteric modulation with arrestin recruitment. In basal conditions, GLP1R and GIPR are proposed to exist mainly as monomers or homodimers, GLP1, under low concentrations (\<30 nM), acts as a high affinity ligand for functioning of GLP1R but switches to become a low affinity ligand to GIPR with high concentrations (\>30 nM). This promotes formation of heterodimers with altered G protein coupling resulting in GIP-like activity that can later be dissociated in the presence of GIP ([@B90]). Heterodimerization of GLP1R and GIPR was also confirmed by a later study with wild-type GLP1R rescuing mutant GIPR function ([@B100]).

VIP/PACAP RECEPTORS
-------------------

To elicit physiological response, vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) bind to three receptors, namely VIPR1, VIPR2, and PACAP receptor type 1 (ADCYAP1R1). Discoveries of VIPR1 and VIPR2 homodimers were made during the study of SCTR oligomerization in 2006 ([@B34]; **Table [1](#T1){ref-type="table"}**). These physical interactions were demonstrated by BRET experiments and found to be modulated by agonist but not antagonist binding ([@B34]). In the same study, BRET results also indicated that VIPR1 and VIPR2 to form hetero-oligomers and VIP binding was found to affect this association negatively ([@B34]; **Table [2](#T2){ref-type="table"}**). Formation of these oligomeric complexes was also supported by co-immunoprecipitation studies ([@B48]). Besides formation of hetero-oligomers between the two subtypes, both VIPRs can oligomerize with SCTR. Interestingly, co-expression of SCTR with either VIPR resulted in strong intracellular FRET signals, suggesting the trapping of hetero-oligomers within organelles of the biosynthetic pathway ([@B34]). Since this retention occurred independent to SCT and VIP stimulation, it has been described as a regulatory step, allowing SCTR to have dominant-negative effects by inhibiting VIP's action on cells expressing both receptors ([@B34]). Within a physiological context, the SCT and VIPR are often co-expressed; therefore information regarding their physical interactions may provide some insights toward diseases such as pancreatic carcinoma ([@B21]; [@B14]). Of the receptor trio, information regarding ADCYAP1R1 oligomerization is scarce with only one study indicating its homodimerization by time-resolved FRET studies ([@B58]; **Table [1](#T1){ref-type="table"}**).

GROWTH HORMONE-RELEASING HORMONE RECEPTORS
------------------------------------------

Growth hormone-releasing hormone (GHRH) is a hypothalamic peptide responsible for stimulating growth hormone release and disruption of the peptide--receptor pair often results in abnormal growth, such as dwarfism or gigantism. GHRHRs have been suggested to form oligomers, with co-expression of mutant and wild-type receptors having dominant-negative effects ([@B61]). The physical interaction amongst GHRHRs was implied with the reduction of ligand binding ability and cyclic adenosine monophosphate (cAMP) production to 60% in presence of truncated receptors ([@B61]). These observations were further supported by detection of both receptor forms by differentially tagged co-immunoprecipitation studies ([@B61]). The relevance of these findings has been hypothesized in the context of pituitary adenomas for example, with preferential expression of the mutant receptor down-regulating signaling and thus modulating growth hormone release ([@B57]).

PARATHYROID HORMONE RECEPTORS
-----------------------------

Parathyroid hormone receptors (PTHRs) play an important role in calcium homeostasis and bone maintenance, mediating the effects of its natural ligands parathyroid hormone (PTH) and PTH-related protein (PTHrP). In 2008 and 2009, the crystal structures of PTH and PTHrP bound human PTHR1 were determined by engineering the receptor as a readily crystallizing maltose binding protein ([@B76]; [@B77]). A "hot dog bun" three-layer α-β-βα fold structure was described, forming the central hydrophobic groove within which the ligands in an amphipathic helical fashion docked ([@B76]; [@B77]). More importantly, the crystal structures depicted ligand binding to PTHR1 ECD monomers in a 1:1 stoichiometric ratio ([@B76]; [@B77]). Interestingly a year later, the crystal structure of ligand-free PTHR1 showed the ECDs as dimers ([@B75]). These ECD dimers were formed in a similar fashion to ligand-bound PTHR1, with the C-terminal of one ECD forming α-helices to occupy the peptide-binding groove of the other ([@B75]). Besides crystallography, BRET and FRET experiments also supported existence of these ECD-mediated PTHR1 homodimers ([@B75]). To confirm the ligand-independent nature of ECD dimerization shown by the crystal structures, PTH was applied to PTHR1s in BRET studies and as predicted, led to agonist-induced dissociation of the PTHR1 homodimers ([@B75]). Furthermore, co-expression of mutant and wild-type ECD PTHR1s showed that monomeric units of the PTHR1 were sufficient for functionality ([@B75]). With the discovery of monomeric and dimeric units of PTHR1, this may be useful in understanding how the two biologically distinct peptides PTH and PTHrP are able to modulate function through binding to the same receptor ([@B75]).

CALCITONIN AND CORTICOTROPIN-RELEASING HORMONE RECEPTORS
--------------------------------------------------------

Targeting mainly osteoblasts, calcitonin is important in calcium homeostasis and has anorexic and analgesic effects in the central nervous system. In a study focused on rabbit calcitonin receptors (CALCRs), homo- and heterodimers of the alternatively spliced CALCR (∆e13) and CALCR type 1a isoform (CALCR1a) were detected by co-immunoprecipitation and FRET analyses ([@B91]). Co-expression resulted in a dominant-negative effect of the splice variant ∆e13 over CALCR1a, resulting in reduced CALCR1a surface expression, cAMP response, and extracellular signal-regulated kinase (ERK) phosphorylation ([@B91]). The combined data highlight the importance of CALCR1a homodimers in proper expression and functioning, and also suggest a role of ∆e13 in regulating CALCR1a expression ([@B91]). In contrast, both static and saturation BRET studies on the human CALCR were found unable to form homodimers ([@B31]). On the basis of SCTR studies where TM4 was identified to be an important interface ([@B35]), the same TM was also considered for CALCR ([@B31]). Comparing human and rabbit TM4 domains, only one single amino acid was found to differ between the two species, namely Arg and His at position 236, respectively ([@B31]). Synthetic TM4 peptides were constructed by exchange of these identified lipid-facing residues to those from respective CALCR species and human SCTR, and their application enhanced human CALCR BRET signals ([@B31]). Similar to the SCTR, lipid-exposed residues in TM4 are also key in facilitating homodimerization events in human CALCR ([@B31]). Though not studied in-depth, the closely related CALCRL has also been demonstrated to exist as homodimers ([@B42]).

Within the class B GPCRs, the corticotropin-releasing hormone receptors (CRHRs) are the least studied. CRHRs are mediators of stress response, modulating the release of adrenocorticotropic hormone from the anterior pituitary. Two subtypes of the receptors exist, but only subtype 1 (CRHR1) has been studied for oligomerization. Data from FRET and co-immunoprecipitation studies show evidence of CRHR1 forming constitutive homodimers independent to ligand binding but their physiological relevance remains unexplored ([@B46]; [@B107]).

FUNCTIONAL CONSEQUENCES OF OLIGOMERIZATION IN CLASS B GPCRs
===========================================================

Within the large superfamily of cell surface proteins, obligatory oligomerization is unique only to class C GPCRs and recognized as a prerequisite for activation and allosteric modulation ([@B44]; [@B11]). However, in the case of class A and B GPCRs where oligomerization has also been established as a real event, the implications on their functions remain unresolved. This is further complicated by the fact that monomeric GPCRs are demonstrated to be independently capable of regulating signal transduction via a series of processes including the activation of G proteins ([@B101]; [@B102], [@B103]; [@B47]), kinase phosphorylation and signal "switch-off" by arrestin binding ([@B106]; [@B5]). To decipher the underlying functional significance, the effect of GPCR oligomerization on various functional properties needs to be examined with emphasis on class B GPCRs, as examples.

LIGAND BINDING
--------------

Ligand binding, either with an agonist or antagonist, is fundamental in activating subsequent downstream signaling cascades. Natural ligands for the class B GPCRs share common features, comprising of 25 or more amino acids and have diffuse pharmacophoric domains ([@B96]). Critical residues have been identified throughout the length of the peptides ([@B18]), with the N-terminus recognized as necessary for receptor binding and signaling, whilst the C-terminus contributes mainly to high affinity binding and receptor specificity. Crystallography ([@B88]; [@B70]) and nuclear magnetic resonance (NMR; [@B27]; [@B97]) analyses have also been useful, elucidating the class B ligands to preferentially assume an α-helical conformation particularly in their C-terminal regions. Structure--activity studies have further implicated the specific interaction of ligand--receptor regions, with the C-terminal ligand domain first fitting into the receptor ECD peptide-binding cleft, thus facilitating the N-terminal ligand domain to associate with the receptor core helical bundle domain ([@B19], [@B17]; [@B56]; [@B71]). Though the molecular interactions described are on the basis of monomeric GPCRs, similar associations may be expected from oligomeric forms. Similarly, molecular modeling and crystallization studies have predicted the binding pockets in SCTR and PTHR homodimers, respectively, to be localized in the extracellular N-terminal domains ([@B24]; [@B75]). Moreover, the SCTR homodimer peptide-binding clefts are demonstrated to reside opposite to the dimerization interfaces that may allow structural freedom for each protomer to bind to its respective ligand in a 1:1 stoichiometric ratio, as expected for monomeric GPCRs ([@B24]). Though limited, the two models show oligomerization to have minimal structural modifications in terms of adequately exposing the binding pockets, allowing ligand--receptor interactions in class B GPCRs.

In majority of studies for this receptor class, the use of peptide or mutant receptors to inhibit dimerization events have been utilized to explore the contribution of such receptor interactions toward functionality. On the basis of these studies, oligomerization has been demonstrated to have differential effects on the ligand binding affinity of class B GPCRs. Using TM4 peptides that are known to disrupt SCTR homodimerization, both monomeric and dimeric SCTR forms were found to have analogous ligand binding properties ([@B35]). Similarly, oligomerization was also found to have null effects on the ligand binding affinity of PTHR1, with the non-dimerizing R179A/V183A double mutant maintaining wild-type PTH binding activity ([@B75]). In another study, CALCR mutants also bound calcitonin saturably with no statistically significant differences in binding affinity ([@B31]). In contrast, disruption of GLP1R homodimerization by TM4 peptides resulted in elimination of G protein-dependent high affinity binding to GLP1(7--36)NH~2~ ([@B36]). Moreover, co-expression of full-length and truncated GHRHRs resulted in a decrease in GHRH ligand binding and has been described to be resultant of the truncated receptor inducing a dominant-negative effect, leading to conformational changes which inhibit proper binding ([@B61]). Nevertheless, these contrasting findings are consistent with recent reports of oligomerization having variable effects on the kinetics and efficiencies amongst receptors ([@B20]; [@B40]). Therefore, oligomerization may be important in modulating receptor activity via altering ligand binding affinity only in certain class B GPCRs.

ALLOSTERY
---------

In recent studies, a link between oligomerization and allosteric regulation has been established in class B GPCRs. Allostery concerns association of a ligand or molecule to the receptor other than its orthosteric site, modifying its functional properties in either a positive or negative manner ([@B60]). Using a classical radio-ligand binding approach, the dissociation of labeled SCT in the absence or presence of unlabeled SCT was monitored to study the negative binding cooperativity of SCTRs ([@B24]). The wild-type dimerizing receptors were found to shift from monophasic to biphasic dissociation upon presence of unlabeled SCT peptide, whilst the non-dimerizing mutant receptors maintained monophasic dissociation, regardless of treatment ([@B24]). On the basis of these results, the homodimeric SCTRs have been speculated to predominantly exist in a G protein-coupled high affinity state and the monomeric forms in a G protein-uncoupled low affinity state ([@B24]). Though the molecular basis responsible for the allosteric effects are still unknown, steric hindrance by the two large extracellular amino-terminal domain or selective coupling may be underlying factors contributing to the negative cooperativity observed in SCTRs ([@B63]). Similarly, the homodimerization event amongst the GCGR and GLP1R have also been identified to exhibit negative cooperativity with addition of labeled native peptides to their respective receptors leading to accelerated dissociation of unlabeled ligands ([@B81]). More recently, the ECD of the GCGR has been demonstrated to act as a negative regulator of receptor activity through interaction with the third extracellular loop ([@B45]), a region not only recognized to contribute to receptor affinity and efficacy, but may also aid in optimizing the arrangement of the TM bundle for efficient ligand binding ([@B72]). As this case, agonist-occupied homodimers may induce negative cooperativity through structural modifications that affect ligand binding. Though the molecular determinants remain to be confirmed, there is a clear relation between dimerization and negative allostery. Aside from the typical ligand-induced allostery, physical coupling of each protomer in a oligomeric complex may also play a role ([@B30]). Within the class B GPCRs, this has only been demonstrated in heteromers of the GLP1R and GIPR, where GIPR is suggested to act allosterically on the GLP1R to decrease maximal responses in calcium flux and β-arrestin recruitment assays ([@B90]). In a later study, mutant GIPR function rescue by wild-type GLP1R was observed, with reduction in GLP1 responsiveness ([@B100]). Again GIPR may be exerting an allosteric effect on GLP1R, but the precise molecular basis needs to be explored with further structural and functional studies.

EFFECTS OF AGONIST OCCUPATION
-----------------------------

Besides allostery, agonist occupation of class B GPCRs can also promote the association or dissociation of oligomeric complexes. In contrast to SCT homodimers that are unaffected by ligand binding ([@B14]; [@B34]), GLP1 binding was found to encourage the dimerization between GLP1R and GIPR ([@B90]). A model proposed describes GLP1 to act as a high affinity ligand for GLP1R at low concentrations, but also becomes a low affinity ligand for GIPR at higher concentrations to trigger formation of the GLP1 and GIPR dimer ([@B90]). Interestingly, the presence of the high affinity GIP reverses the GLP1 induced association, dissolving the heteromer to a monomeric state ([@B90]). As previously discussed, the GIPR has allosteric effects on the GLP1R when heterodimerized. Taken together with the agonist-induced association and/or dissociation of receptors, this may be a mechanism by which the receptors activate their G proteins and subsequent downstream signaling cascades ([@B26]). Agonist-induced dissociation has also been reported for the PTHR1 via structural mimicry of PTH/PTHrP binding ([@B75]), however the functional relevance remains unclear. Other examples of agonist-induced disruption of oligomerization include VIPR1 and VIPR2 homodimers and VIPR1/VIPR2 heterodimers ([@B34]).

SIGNALING
---------

Another prominent effect of oligomerization in class B GPCRs is on signaling selectivity and efficiency. In particular, cAMP and PLC are two of the predominant pathways in which physiological responses are elicited through in class B GPCRs. Therefore most oligomerization studies have extended their focus beyond information from ligand binding and BRET studies, but also rely on the cAMP and calcium mobilization responses of receptors. In particular, SCTRs are one of the first class B GPCRs demonstrated to have altered functionality due to homodimerization. By TM4 peptide competition studies, the disruption of SCTR dimerization was found to result in impairment of the generation of cAMP ([@B35]). The dimeric form of SCTR was, therefore, suggested be the optimal conformation for G protein activation ([@B35]). Similarly, disruption of the GLP1R homodimers was found to not only affect cAMP formation and ERK phosphorylation, but also lead to a complete loss of intracellular calcium mobilization response ([@B36]). In the case of GLP1R homodimers, signal transduction involves more than one G protein and/or accessory proteins such as β-arrestins. Nonetheless, dimerization is likely the basis in altering G protein coupling efficiency ([@B36]). This was also evident in the heterodimerization of GLP1 and GIP receptors, with the heteromer having more "GIP-like" ([@B90]) pharmacological characteristics. Based on most of the studied class B GPCRs, oligomerization seems to exhibit a general trend in affecting G protein activation and signaling efficiency. However, oligomerization should not be a prerequisite for signaling, as monomers such as the PTHRs have been demonstrated to be capable of activating G proteins on their own ([@B75]). Therefore, oligomerization is likely important in providing structural framework to facilitate G protein coupling and thus modulate function.

TRAFFICKING
-----------

A number of studies have suggested the importance of oligomerization in cellular trafficking of the receptors and is a process that occurs early in the biosynthetic pathway ([@B7]). Within the class B GPCRs, this aspect of oligomerization has been most thoroughly explored for the SCTRs. Indeed using a combination of fluorescence and morphologic FRET microscopy studies, the SCTR homodimers were localized within organelles of the biosynthetic pathway including the tubular endoplasmic reticulum, Golgi clusters and the plasma membrane ([@B54]). The homodimerization of SCTRs has therefore been suggested to occur as early as newly synthesized receptors and continue throughout their maturation process ([@B54]). Moreover, non-dimerizing SCTR constructs were not expressed nor yielded a significant morphological FRET signal both intracellularly and on the plasma membrane ([@B35]). Taken together, the SCTR data support the idea that oligomerization may be necessary for receptors to by-pass quality checkpoints before being delivered to their site of action ([@B7]). Consistent with the SCTR data, the VIPRs have also been identified in the biosynthetic pathway and plasma membrane as homo- and heterodimeric complexes ([@B34]). Interestingly, heterodimerization involving the SCTR and VIPR impaired trafficking to the plasma membrane with morphological FRET analyses revealing these heteromers to be trapped within the biosynthetic pathway, lacking cell surface expression ([@B34]). In the case of VIPRs, heterodimerization with SCTR predominates over the homodimerization of VIPRs ([@B34]). This demonstrates dominant-negative inhibition of oligomerization on cellular trafficking, which may be useful for modulating function in cells expressing both the SCTR and VIPR ([@B34]). In a later study, a small amount of mutant GIPR completely lacking *N*-glycosylation and cell surface expression was rescued by co-expression with GLP1R but not GIPR, suggesting the possibility of a heteromer which has a dominant-positive effect in facilitating the trafficking of GIPR ([@B100]).

STRUCTURAL ELEMENTS GOVERNING OLIGOMERIZATION IN CLASS B GPCRs
==============================================================

With the class B GPCRs key in a number of pathophysiological diseases and mounting evidence indicating their oligomerization to have influence in modulating various functional properties, this has fueled research in unraveling the structural determinants. To date, majority of studies have suggested the importance of different domains in GPCR oligomerization. However within the class B GPCRs, a common theme seems to prevail with several lines of evidence indicating the TM domains to be important. More specifically, it is the fourth TM domain, which has been implicated as a key molecular domain in class B receptor homodimerization (**Table [1](#T1){ref-type="table"}**). This has been well documented by the disruption of SCTR homodimerization by TM4 peptides, with mutation studies identifying the lipid-facing residues namely Gly^243^ and Ile^247^ as important interfaces ([@B35]). Similarly, TM4 also provides the primary interface for GLP1R homodimerization, as supported by experimental data with TM4 peptide treatment dissociating the complex ([@B36]). Consistent with findings from the SCTR studies, lipid-facing residues within TM4 of the CALCR were also found to be necessary for dimerization ([@B31]). Though TM4 has been indicated to provide basis for dimerization in class B GPCRs, other domains including the ECD in PTHR ([@B75]) and C-terminal tail in CALCR ([@B31]) may also have some role. More recently, a pseudo signal peptide unique to the CRHR2a was identified to inhibit oligomerization ([@B94]). Steric hindrance by the bulky nature of the high mannose glycan protruding from this N-terminal domain has been suggested, thus preserving CRHR2a as monomers ([@B94]). Current prediction programs are unable to differentiate between canonical and pseudo signal peptides, as a result the presence of similar structures may also exist in other class B GPCRs ([@B85]; [@B94]). Taken together, dimerization of class B GPCRs may not necessarily be dependent solely on one structural motif but instead is a highly complex interaction amongst several domains to achieve optimal structural basis for the fine-tuning of physiological processes.

FUTURE PERSPECTIVES
===================

Over the last three decades, there has been a rapid development of techniques for studying the molecular interaction between GPCRs. Though early evidence was largely overlooked and limited to the class A GPCRS, establishment of RET techniques, in particular, have led to reinterpretation and strongly supports the concept of GPCR oligomerization. In recent years, class B GPCRs are also gaining merit in their ability to form homo- and hetero- oligomers, with the SCTRs being the most extensively studied. Though still nascent, the information available supports the role of dimerization in modulating function of class B GPCRs. Naturally, ligand binding to a receptor results in conformational changes in G protein arrangement to elicit downstream signaling pathways. When GPCRs associate, conformational arrangements also occur to modulate functionality. For example, SCTR homodimers have greater signaling responses than its monomeric counterparts. Furthermore, GPCR dimerization may also act as a repair mechanism, *trans*-complementing domains to restore binding sites and thus signaling, as observed for spliced SCTRs ([@B14],[@B15]). In terms of trafficking, oligomerization may also play a role with evidence of SCTR homodimers present as early as nascent molecules throughout the biosynthetic pathway ([@B54]). Though seemingly simple when considering homodimeric units, evidence of GPCR heterodimerization, for example of SCTRs with a wide range of class B GPCRs, such as VIPR and GCGR, suggests a more complex role. Attempts have also been made to link these physical characteristics to pathophysiological responses in class B GPCRs, for example, association of SCTR homodimers to gastrinoma ([@B15]) and GLP1R/GIPR heterodimers to diabetes ([@B100]). GPCR oligomerization is therefore functionally relevant and further research will be useful in providing more insights in understanding the molecular determinants to *in vivo* responses and for drug design.
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